Source:http://linkedlifedata.com/resource/pubmed/id/15924593
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0010186,
umls-concept:C0017168,
umls-concept:C0030705,
umls-concept:C0033522,
umls-concept:C0034656,
umls-concept:C0034665,
umls-concept:C0087111,
umls-concept:C0205246,
umls-concept:C0205476,
umls-concept:C0220812,
umls-concept:C0337812,
umls-concept:C0542559,
umls-concept:C0679199,
umls-concept:C0937846,
umls-concept:C1273870,
umls-concept:C1280519,
umls-concept:C1457887,
umls-concept:C1709627
|
| pubmed:issue |
6
|
| pubmed:dateCreated |
2005-5-31
|
| pubmed:abstractText |
This study assesses the difference in direct medical costs between on-demand treatment with esomeprazole 20 mg, continuous treatment with esomeprazole 20 mg once-daily and continuous treatment with ranitidine 150 mg twice-daily to prevent symptomatic relapse in patients with gastroesophageal reflux disease over 26 weeks. Two hundred eighty-one GP clinics in Norway enrolled 2156 patients to an open, randomized, parallel group, Norwegian society perspective study during 2000-2001. The total direct medical costs of each strategy were 171.9 Euros for on-demand esomeprazole (n = 634), 221.6 Euros for ranitidine (n = 610) and 248.8 Euros for continuous esomeprazole (n = 658). The total costs for on-demand and continuous esomeprazole treatment and ranitidine treatment were 221.5, 286.5 and 295.8 Euros, respectively. The highest proportion of costs was because of the study medication cost in each strategy. The on-demand and continuous treatment strategies with esomeprazole were found to be cost-effective, compared with ranitidine.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1368-5031
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
59
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
655-64
|
| pubmed:dateRevised |
2007-2-14
|
| pubmed:meshHeading |
pubmed-meshheading:15924593-Adult,
pubmed-meshheading:15924593-Anti-Ulcer Agents,
pubmed-meshheading:15924593-Cost-Benefit Analysis,
pubmed-meshheading:15924593-Drug Costs,
pubmed-meshheading:15924593-Female,
pubmed-meshheading:15924593-Gastroesophageal Reflux,
pubmed-meshheading:15924593-Humans,
pubmed-meshheading:15924593-Long-Term Care,
pubmed-meshheading:15924593-Male,
pubmed-meshheading:15924593-Middle Aged,
pubmed-meshheading:15924593-Norway,
pubmed-meshheading:15924593-Omeprazole,
pubmed-meshheading:15924593-Patient Satisfaction,
pubmed-meshheading:15924593-Prospective Studies,
pubmed-meshheading:15924593-Proton Pumps,
pubmed-meshheading:15924593-Ranitidine
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Six-month management of patients following treatment for gastroesophageal reflux disease symptoms -- a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting.
|
| pubmed:affiliation |
Harbitzallèen Legesenter, Oslo, Norway. age.normanhansen@harbitzalleen.onh.no
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|